Compare QSI & PCRX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | QSI | PCRX |
|---|---|---|
| Founded | 2013 | 2006 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 273.7M | 1.0B |
| IPO Year | N/A | 2011 |
| Metric | QSI | PCRX |
|---|---|---|
| Price | $1.28 | $25.98 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 3 | 7 |
| Target Price | $2.63 | ★ $32.86 |
| AVG Volume (30 Days) | ★ 4.2M | 892.3K |
| Earning Date | 11-05-2025 | 11-06-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | ★ 0.47 |
| Revenue | $3,177,000.00 | ★ $716,791,000.00 |
| Revenue This Year | N/A | $6.24 |
| Revenue Next Year | $159.68 | $9.53 |
| P/E Ratio | ★ N/A | $54.61 |
| Revenue Growth | ★ 40.20 | 3.14 |
| 52 Week Low | $0.95 | $18.17 |
| 52 Week High | $5.77 | $27.64 |
| Indicator | QSI | PCRX |
|---|---|---|
| Relative Strength Index (RSI) | 42.85 | 59.78 |
| Support Level | $1.20 | $25.48 |
| Resistance Level | $1.32 | $27.16 |
| Average True Range (ATR) | 0.09 | 1.01 |
| MACD | 0.01 | 0.00 |
| Stochastic Oscillator | 27.78 | 66.13 |
Quantum-Si Inc is a life sciences company focused on the development and commercialization of proteomics research tools. The company has designed and developed a hardware, consumable, and software solution to provide a solution for protein detection and analysis. It has developed a proprietary universal single-molecule detection platform that enables Next-Generation Protein Sequencing (NGPS), the ability to sequence proteins.
Pacira BioSciences Inc is a provider of non-opioid pain management and regenerative health solutions dedicated to advancing and improving outcomes for healthcare practitioners and their patients. The company's commercialized non-opioid treatments: EXPAREL a long-acting, local analgesic currently approved for postsurgical pain management; ZILRETTA, an extended-release, intra-articular, corticosteroid injection indicated for the management of osteoarthritis; and iovera, a novel, handheld device for delivering immediate, long-acting, drug-free pain control using precise, controlled doses of cold temperature to a targeted nerve. In addition, it is developing PCRX-201 (enekinragene inzadenovec), a novel gene therapy vector platform for the treatment of osteoarthritis of the knee.